ProfileGDS5678 / 1416090_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 93% 95% 94% 94% 94% 94% 95% 96% 95% 93% 95% 94% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.9920894
GSM967853U87-EV human glioblastoma xenograft - Control 28.0561393
GSM967854U87-EV human glioblastoma xenograft - Control 38.4844195
GSM967855U87-EV human glioblastoma xenograft - Control 48.4489894
GSM967856U87-EV human glioblastoma xenograft - Control 58.2732494
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.7692394
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.8517494
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.5751795
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.7376996
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.3230895
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.8472693
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.3398495
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.1397794
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.2536494